CN102266346B - Medicament for preventing and controlling coccidiosis - Google Patents
Medicament for preventing and controlling coccidiosis Download PDFInfo
- Publication number
- CN102266346B CN102266346B CN 201110171362 CN201110171362A CN102266346B CN 102266346 B CN102266346 B CN 102266346B CN 201110171362 CN201110171362 CN 201110171362 CN 201110171362 A CN201110171362 A CN 201110171362A CN 102266346 B CN102266346 B CN 102266346B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicament
- coccidiosis
- milligrams
- metronidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicament for preventing and controlling coccidiosis, which belongs to the technical field of veterinary medicines. The medicament comprises the following components in part by weight: 450 to 600 parts of sulfamonomethoxine, 110 to 130 parts of diaveridine, 145 to 180 parts of metronidazole and 80 to 160 parts of etamcylate. When the medicament is used, feed blended by mixing 450 to 600 milligrams of sulfamonomethoxine, 110 to 130 milligrams of diaveridine, 145 to 180 milligrams of metronidazole and 80 to 160 milligrams of etamcylate with each kilogram of feed is eaten by sick poultry freely, and the medicament has a good prevention and treatment effect on the coccidiosis under the synergistic action of the components. Experiments indicate that an anticoccidial index of the medicament is higher than that of each single medicine. Simultaneously, coccidial infection accompanies anaerobe infection, the anticoccidial effect of principal ingredients can be played effectively by the addition of the metronidazole, and antimicrobial spectra also can be enlarged further, so the clinical treatment of the coccidiosis is facilitated.
Description
Technical field
The invention belongs to the veterinary drug technical field, be specifically related to a kind of medicine of preventing and treating coccidiosis.
Background technology
Coccidiosis is a kind of parasitic disease that is caused by unicellular parasite Eimeria (Amy ear), can cause poultry meat, egg production serious loss to occur.The fresh egg capsule of discharging with the feces that infects poultry does not have appeal, is called " not spore egg capsule ".These not the spore egg capsule need under suitable external condition (temperature, humidity, partial pressure of oxygen), carry out Sporogony, through 1 ~ 2 day after, just growing is the spore egg capsule that infection ability is arranged.After being eaten by the susceptible poultry, the spore egg capsule under the muscular stomach wearing and tearing, disengages Sporangium.The Sporangium that gets into small intestinal with food disengages zygoblast under enzyme (mainly being trypsin) and biliary effect, zygoblast is invaded epithelial cell, after schizogony, forms many merozoites.Merozoite can be gone schizogony again, forms more merozoites.Coccidiosis is pathogenic the strongest in the schizogony stage, because of polypide breeds repeatedly, has destroyed a large amount of intestinal submucosa tissues and blood capillary, and the massive blood loss that causes thus, gut epithelium considerable damage and secondary infection are to cause being infected poultry or sick fowl main causes of death.
Birdss such as chicken, duck, goose, turkey, Carnis Coturnicis japonicae, peafowl, Ostriches all can infect coccidiosis.The intensive culture field is because stocking density is big, and logistics is frequent, and coccidian oocyst quantity is big and concentrated relatively, is the optimum place that coccidiosis breaks out therefore, and sickness rate is about 50% ~ 70%; Mortality rate 20% ~ 30%, when serious even up to 80%, very harmful.
Summary of the invention
The objective of the invention is for a kind of medicine that can effectively prevent and treat coccidiosis is provided.
Based on above-mentioned purpose, the technical scheme that the present invention takes is: a kind of medicine of preventing and treating coccidiosis, it consists of: 450 ~ 600 parts of sulfamonomethoxines, 110 ~ 130 parts of NSC 408735s, 145 ~ 180 parts of metronidazoles, 80 ~ 160 parts of etamsylates (etamsylate).
Medicine of the present invention forms by multiple active ingredient is composite, and each component has mutual synergism.During use; Supply sick fowl free choice feeding after the consumption of admixing sulfamonomethoxine 450 ~ 600mg, NSC 408735 110 ~ 130mg, metronidazole 145 ~ 180mg, etamsylate 80 ~ 160mg according to every kg feedstuff prepares feedstuff, coccidiosis is had fabulous prevention and therapeutic effect.Test shows that the anticoccidial index of this medicine is higher than each single medicine.Simultaneously, coccidium infection is many with anaerobic infection, and the effect of principal agent performance anticoccidial not only can be effectively worked in coordination with in the adding of metronidazole, also can further enlarge antimicrobial spectrum, more helps the clinical treatment of coccidiosis.
The specific embodiment
Below in conjunction with specific embodiment the present invention is described further.
Embodiment 1:A kind of medicine of preventing and treating coccidiosis, it consists of: 450 parts of sulfamonomethoxines, 110 parts of NSC 408735s, 145 parts of metronidazoles, 80 parts of etamsylates.
Embodiment 2:A kind of medicine of preventing and treating coccidiosis, it consists of: 520 parts of sulfamonomethoxines, 120 parts of NSC 408735s, 170 parts of metronidazoles, 110 parts of etamsylates.
Embodiment 3:A kind of medicine of preventing and treating coccidiosis, it consists of: 600 parts of sulfamonomethoxines, 130 parts of NSC 408735s, 180 parts of metronidazoles, 160 parts of etamsylates.
Effect test
One, test material
1.1 experimental animal
1 age in days Luo Man egg cock broods under the non-ball worm environment to 12 ages in days, weighs, divides into groups behind the pretest inspection non-ball worm egg capsule.
1.2 test coccidiosis worm strain
The Zhengzhou strain of tender eimeria tenella, effluent south agriculture university parazoon test chamber provides.
1.3 trial drug
Sulfanilamide is to a Sulfamonomethoxine, SDM, metronidazole, and compositions of the present invention.
Because the etamsylate among the present invention belongs to symptomatic drugs, is not the anticoccidial composition, so do not check its anticoccidial effect separately.
Two, test method
2.1 test is divided into groups
According to the body weight dispersion, test chicken is divided into 7 groups at random, 15 every group, record is starting weight just.The 1st～5 group for infecting the medication group, and the 6th group for infecting not medication group, and the 7th group for not infecting not medication group.
2.2 infect and administration
Except that the 7th group, other respectively organizes chicken (the 1st～6 group) all in 12 age in days oral vaccination coccidian oocysts 2.0 * 10
5Individual/only.With reference to the table 1 in " gluconic acid is to the influence of meat chicken production performance and nutrient apparent digestibility " (Chinese poultry, 2009 31 volume 16 phase p16) preparation basal diet; 1～5 group in infect back 48h throw something and feed be mixed with relative medicine basal diet to off-test, and the 6th group and the 7th group of basal diet of only throwing something and feeding.Specifically mix dose and see 1.
Duration of test observed and recorded every day is respectively organized mental status, appetite, drinking-water and the feces situation of chicken, and morbidity and the death condition of chicken respectively organized in record, and the inspection and the record cause of death are weighed, cutd open to dead chicken at any time.The 6th day gram feces egg capsule output (OPG) behind the calculating counteracting toxic substances; Behind the counteracting toxic substances the 8th day, test chicken all weighed, cuts open on an empty stomach kill, carry out lesion score, measure corresponding test index, measure the result and see table 1.
Three, result of the test
ACI be objective, accurately estimate the curative effect index of anticoccidial drug, calculate by the method for Merck & Co., Inc. (Merck), that is: ACI=(the relative weight gain rate+survival rate) * 100-(pathological changes value+egg capsule value).ACI＜120 are invalid, and ACI=120～160 are medium effective, and ACI=160～180 are that drug effect is good, and ACI＞180 are efficient.
The 4th day chicken began to discharge a small amount of hemafecia after the 6th group (matched group) infected coccidiosis, the 5th, 6,7 day, especially the 6th day the most serious, discharge a large amount of hemafecias; Spirit is depressed, and necking down is slow-witted upright, and drowsiness, feather is fluffy and disorderly; Lack food or do not eat appearance death, survival rate 60.00%, pathological changes value 32.67; Egg capsule value 20, anticoccidial index (ACI) is merely 82.98, and this shows the success of this test coccidium infection.
Can find out that from table 1 sulfamonomethoxine, NSC 408735, metronidazole all can improve anticoccidial ACI, but effect is far away from composition of medicine of the present invention.The anticoccidial Index A CI of composition of medicine of the present invention is 186.33, apparently higher than the effect of single (1-3 group) or simply composite (4 groups) medicine, and belongs to efficient anticoccidial combination.Test confirms that medicine of the present invention has chicken coccidiosis excellent curative is arranged.
Claims (1)
1. medicine of preventing and treating coccidiosis, it consists of: 450 ~ 600 parts of sulfamonomethoxines, 110 ~ 130 parts of NSC 408735s, 145 ~ 180 parts of metronidazoles, 80 ~ 160 parts of etamsylates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110171362 CN102266346B (en) | 2011-06-24 | 2011-06-24 | Medicament for preventing and controlling coccidiosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110171362 CN102266346B (en) | 2011-06-24 | 2011-06-24 | Medicament for preventing and controlling coccidiosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102266346A CN102266346A (en) | 2011-12-07 |
| CN102266346B true CN102266346B (en) | 2012-06-13 |
Family
ID=45048931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110171362 Expired - Fee Related CN102266346B (en) | 2011-06-24 | 2011-06-24 | Medicament for preventing and controlling coccidiosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102266346B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070907B (en) * | 2012-12-28 | 2014-11-12 | 漳州师范学院 | Medicine resistant to poultry coccidiosis and preparation method thereof |
| CN108524913A (en) * | 2018-05-26 | 2018-09-14 | 谢媛 | A kind of medicine and preparation method thereof of prevention Penaeus Vannmei intestinal bacteria disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1233467A (en) * | 1999-02-01 | 1999-11-03 | 华南农业大学 | Anti-coccidium medicinal prepn. |
| CN101450055A (en) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating livestock and poultry bacterial infection and parasitic disease |
-
2011
- 2011-06-24 CN CN 201110171362 patent/CN102266346B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1233467A (en) * | 1999-02-01 | 1999-11-03 | 华南农业大学 | Anti-coccidium medicinal prepn. |
| CN101450055A (en) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating livestock and poultry bacterial infection and parasitic disease |
Non-Patent Citations (3)
| Title |
|---|
| 孙九才.不同治疗方法对奶牛球虫病疗效观察.《黑龙江畜牧兽医》.1998,(第9期),27. * |
| 曾庆德 等.应用甲硝唑治疗肉鸡慢性球虫病.《当代畜禽养殖业》.2004,(第1期),26. * |
| 王锋等.鸡球虫病防治的研究进展.《河北农业科学》.2008,第12卷(第1期),128-130. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102266346A (en) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rodgers et al. | Antimicrobial agents in aquaculture: practice, needs and issues | |
| Talpur et al. | Dietary effects of garlic (Allium sativum) on haemato-immunological parameters, survival, growth, and disease resistance against Vibrio harveyi infection in Asian sea bass, Lates calcarifer (Bloch) | |
| ES2406423T3 (en) | Abdominal bloating control agent for ruminant animals | |
| CN103006792B (en) | A kind of herbal medicine for preventing and treating livestock and poultry intestinal canal diseases and preparation method thereof and feed | |
| Wangkahart et al. | Optimum dietary sources and levels of selenium improve growth, antioxidant status, and disease resistance: re-evaluation in a farmed fish species, Nile tilapia (Oreochromis niloticus) | |
| Sattanathan et al. | Influences of dietary inclusion of algae Chaetomorpha aerea enhanced growth performance, immunity, haematological response and disease resistance of Labeo rohita challenged with Aeromonas hydrophila | |
| CN101757605A (en) | Medicine for preventing fish bacterial enteritis | |
| Kawano et al. | Antiparasitic effect of dietary Romet® 30 (SDMX–OMP) against ciliate Cryptocaryon irritans infection in the red sea bream Pagrus major and tiger puffer Takifugu rubripes | |
| Bilen et al. | Modulatory effects of laurel-leaf cistus (Cistus laurifolius) ethanolic extract on innate immune responses and disease resistance in common carp (Cyprinus carpio) | |
| CN102920771B (en) | Medicine for treating poultry coccidiosis | |
| CN102266346B (en) | Medicament for preventing and controlling coccidiosis | |
| CN103070907B (en) | Medicine resistant to poultry coccidiosis and preparation method thereof | |
| Rodrigues et al. | Feeding frequency affects feed intake and growth in juvenile pirarucu (Arapaima gigas) | |
| CN102641261B (en) | Application of Vorinostat in preparation of soft-resistant Eimeria drugs | |
| JP2018501294A (en) | Application of taurine in the prevention and / or treatment of diseases caused by coronavirus and / or rotavirus viruses | |
| JPWO2009139468A1 (en) | Coccidiosis control agent and feed containing the same | |
| CN102028677B (en) | Application of juglone nucin in preparing medicine for resistance to eimeria tenella | |
| Neepa et al. | Improvement of growth and hematological profile of juvenile silver barb (Barbonymus gonionotus) through dietary probiotic (Bacillus sp.) supplementation | |
| US9687545B2 (en) | Nonspecific immunostimulator composition, method of preparation the same, and its use | |
| CN105746940B (en) | A kind of multidimensional premix improving Penaeus Vannmei intestinal health | |
| Fajer-Avila et al. | Effectiveness of oral Elancoban™ and Avimix-ST™ against Nematopsis (Apicomplexa: Porosporidae) gametocyts infecting the shrimp Litopenaeus vannamei | |
| CN106668038A (en) | Application of rhodosin in preparing anti-eimeria tenella drug | |
| JP6141841B2 (en) | Crustacean feed | |
| JPH0840935A (en) | Method of giving immunity against poultry coccidiosis | |
| Hung et al. | In vitro effects of singular or combined anti-oxidative vitamins and/or minerals on tilapia (Oreochromis hybrids) peripheral blood monocyte-derived, anterior kidney-derived, and spleen-derived macrophages |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120613 Termination date: 20150624 |
|
| EXPY | Termination of patent right or utility model |